|
| |
 |
|
| IMAGE OF THE MONTH |
|
| Year : 2020 | Volume
: 1
| Issue : 1 | Page : 40 |
|
Ac 225 quinoline theragnosis in recurrent advanced ovarian cancer
K Kallur, Prasanth
Department of Nuclear Medicine and Imaging, HCG Cancer Centre, India
| Date of Web Publication | 22-Oct-2020 |
Correspondence Address:
Dr. K Kallur
Department of Nuclear Medicine and Imaging, HCG Cancer Centre, Bangaluru
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/WKMP-0197.298283
How to cite this article:
Kallur K, Prasanth. Ac 225 quinoline theragnosis in recurrent advanced ovarian cancer. J Precis Oncol 2020;1:40 |
A case of Carcinoma Ovary presented to us in January, 2015 with metastatic disease. She was treated with Chemotherapy with complete response.
In November 2016, when she relapsed, standard chemotherapy regimen was started. However, there was no significant benefit. The disease progressed and developed Ascites requiring Ascitic tap twice a week. A novel regimen of Ac 225- Quinoline derivative therapy with three courses of weekly Cisplatin and with significant response (Figure). The ascites reduced and her lesion regressed completely achieving complete response. Today, patient has a good quality of life and doing well.
| Discussion | |  |
Ac 225 Quinoline derivative targets the tumour stroma. Ac 225 is an Alpha emitting isotope with 10 days half-life [1]. Ac 225 linked to Quinoline derivative selectively targets cancer associated fibroblasts (CAF) in the tumour. It is highly specific and targets the CAF which are found only in the malignant tissue. As a result, there is no non-specific uptake of the isotope elsewhere in the body. The side effects are limited considering the high specificity. CAF have been implicated in resistance to chemotherapy. When this stroma is destroyed by the alpha radiation, the tumour becomes responsive to chemotherapy.
| References | | |
| 1. | Morgenstern A, Apostolidis C, Kratochwil C, et al. An Overview of Targeted Alpha Therapy with 225 Actinium and 213 Bismuth. Curr Radiopharm. 2018;11(3):200-208. doi:10.2174/1874471011666180502104524  |
|
Search Pubmed for